EpiPen fallout builds as adviser backs dumping Mylan board
Washington
MYLAN faces an increasing backlash over its handling of the EpiPen pricing controversy, as a top proxy adviser urged shareholders to oust the drugmaker's board.
Institutional Shareholder Services (ISS) said that the company's directors had failed to stop "significant destruction in shareholder value". ISS took issue with the company's governance on a broad scale and faulted the board for making "egregious" decisions on pay.
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Over 150 customers engage law firm, seek legal advice in Cordlife case
Prada not looking at M&A, sees ‘positive surprise’ from US: CEO
AstraZeneca to build US$1.5 billion manufacturing plant in Singapore
Genting open to integrated casino resort in UAE: Chairman Lim Kok Thay
SFA to improve fish farming infrastructure in southern waters after Barramundi Group exits
Another Cordlife director arrested amid CAD probe